Appointment of Non-Executive Independent Directors Mr. Anshu Agarwal and Mrs. Sonal Desai.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals' board, at its meeting on 30th July 2025, approved unaudited financial results for Q1 FY26 (quarter ended 30th June 2025). Net sales surged about 54% year-on-year to Rs 11,940.29 lakhs from Rs 7,753.58 lakhs, while profit after tax rose nearly 64% to Rs 676.58 lakhs (from Rs 412.99 lakhs), pushing EPS up to Rs 14.33 versus Rs 8.79 a year ago. The board also appointed Mr. Anshu Agarwal (Chartered Accountant, Audit Associate at Fust Charles LLP) and Ms. Sonal Desai (Company Secretary with pharma and governance experience) as Non-Executive Independent Directors for a five-year term, subject to shareholder approval. Both are confirmed independent of the promoter group and not debarred by SEBI. Limited review on both standalone and consolidated results was carried out by statutory auditor R.H. Nisar & Co. with an unmodified conclusion.
Strong double-digit revenue and profit growth signals improving business momentum, likely to be viewed positively by shareholders. Adding two independent directors strengthens board composition and governance, with the appointees bringing finance and corporate compliance expertise respectively.